CRISPR Therapeutics achieved a major scientific milestone last month with the U.K. approval of Casgevy, the first in the world for a CRISPR medicine. Wall Street analysts are expecting a similar outcome with U.S. regulators.
Yet the sales outlook for Casgevy are unclear, and CRISPR partner Vertex Pharmaceuticals leads commercialization. For CRISPR to become profitable, some of its other programs will need to succeed as well.
The company lost about $112 million in the third quarter, and Fierce Biotech recently reported the company laid off some staff before Casgevy’s U.K. approval.
